Kynurenic Acid Accelerates Healing of Corneal Epithelium In Vitro and In Vivo.
accelerated healing
conjunctival epithelium
corneal epithelium
kynurenic acid
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
30 Jul 2021
30 Jul 2021
Historique:
received:
04
07
2021
revised:
26
07
2021
accepted:
28
07
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
Kynurenic acid (KYNA) is an endogenous compound with a multidirectional effect. It possesses antiapoptotic, anti-inflammatory, and antioxidative properties that may be beneficial in the treatment of corneal injuries. Moreover, KYNA has been used successfully to improve the healing outcome of skin wounds. The aim of the present study is to evaluate the effects of KYNA on corneal and conjunctival cells in vitro and the re-epithelization of corneal erosion in rabbits in vivo. Normal human corneal epithelial cell (10.014 pRSV-T) and conjunctival epithelial cell (HC0597) lines were used. Cellular metabolism, cell viability, transwell migration, and the secretion of IL-1β, IL-6, and IL-10 were determined. In rabbits, after corneal de-epithelization, eye drops containing 0.002% and 1% KYNA were applied five times a day until full recovery. KYNA decreased metabolism but did not affect the proliferation of the corneal epithelium. It decreased both the metabolism and proliferation of conjunctival epithelium. KYNA enhanced the migration of corneal but not conjunctival epithelial cells. KYNA reduced the secretion of IL-1β and IL-6 from the corneal epithelium, leaving IL-10 secretion unaffected. The release of all studied cytokines from the conjunctival epithelium exposed to KYNA was unchanged. KYNA at higher concentration accelerated the healing of the corneal epithelium. These favorable properties of KYNA suggest that KYNA containing topical pharmaceutical products can be used in the treatment of ocular surface diseases.
Identifiants
pubmed: 34451850
pii: ph14080753
doi: 10.3390/ph14080753
pmc: PMC8398234
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Foundation for Polish Science
ID : POMOST/2013-7/15
Références
PLoS One. 2012;7(9):e44574
pubmed: 22970252
Int J Tryptophan Res. 2013 Sep 04;6:47-55
pubmed: 24049450
Pharmacol Rep. 2009 Jul-Aug;61(4):751-6
pubmed: 19815960
PLoS One. 2015 Jul 27;10(7):e0134157
pubmed: 26214847
J Headache Pain. 2015;16:99
pubmed: 26627709
Plant Foods Hum Nutr. 2012 Mar;67(1):17-23
pubmed: 22392498
Toxicol Sci. 2010 May;115(1):89-97
pubmed: 20106948
Neuropharmacology. 2016 Sep;108:136-43
pubmed: 27131920
Mol Med Rep. 2014 Jun;9(6):2245-50
pubmed: 24676597
Trends Pharmacol Sci. 2013 Feb;34(2):136-43
pubmed: 23123095
J Vet Sci. 2013;14(1):61-7
pubmed: 23388445
Ophthalmic Res. 2013;50(2):129-33
pubmed: 23941990
Ocul Immunol Inflamm. 2012 Dec;20(6):406-18
pubmed: 23163602
Toxicol Sci. 2010 Apr;114(2):217-25
pubmed: 20044593
Arch Biochem Biophys. 2008 Mar 15;471(2):215-23
pubmed: 18242161
J Pharm Sci. 2018 Jun;107(6):1572-1576
pubmed: 29421218
Spectrochim Acta A Mol Biomol Spectrosc. 2014 Aug 14;129:457-65
pubmed: 24751782
Mol Vis. 2017 Jun 26;23:364-371
pubmed: 28706436
Stem Cell Res. 2010 Nov;5(3):188-200
pubmed: 20813601
Arch Ophthalmol. 1992 Sep;110(9):1292-4
pubmed: 1520119
Integr Biol (Camb). 2017 May 22;9(5):451-463
pubmed: 28425521
Expert Rev Neurother. 2015;15(7):719-21
pubmed: 26004930
Pharmacol Rep. 2017 Aug;69(4):722-729
pubmed: 28551532
J Cataract Refract Surg. 1997 Dec;23(10):1515-20
pubmed: 9456409
Int J Ophthalmol. 2020 Feb 18;13(2):199-205
pubmed: 32090027
Br J Ophthalmol. 1998 Dec;82(12):1407-11
pubmed: 9930272
Int J Mol Sci. 2020 Sep 16;21(18):
pubmed: 32947781
Exp Eye Res. 2009 Aug;89(2):124-5
pubmed: 19254714
Curr Med Chem. 2017;24(33):3649-3665
pubmed: 28707585
Neurosci Lett. 1988 Jul 19;90(1-2):208-12
pubmed: 3412643
Pharmacol Res. 2017 Sep;123:27-39
pubmed: 28648739
Exp Eye Res. 2014 Aug;125:183-92
pubmed: 24971496
Front Neurol. 2018 Jan 16;8:745
pubmed: 29387039
J Neural Transm (Vienna). 2012 Feb;119(2):133-9
pubmed: 22215208
Ocul Surf. 2015 Jul;13(3):204-212.e1
pubmed: 26045234
Ophthalmic Res. 2008;40(5):249-56
pubmed: 18437035
Biochem Pharmacol. 2009 Feb 15;77(4):588-96
pubmed: 18983832
PLoS One. 2014 Mar 17;9(3):e91955
pubmed: 24637853
Front Immunol. 2018 Jan 10;8:1957
pubmed: 29379504
Ophthalmic Res. 2004 Mar-Apr;36(2):124-8
pubmed: 15017110
Free Radic Biol Med. 2021 Aug 20;172:331-339
pubmed: 34146664
Graefes Arch Clin Exp Ophthalmol. 2008 Oct;246(10):1455-61
pubmed: 18642018
AMA Arch Ophthalmol. 1957 Aug;58(2):193-201
pubmed: 13443577
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):948-56
pubmed: 11274071
Clin Chim Acta. 2015 Oct 23;450:316-21
pubmed: 26343924
Photochem Photobiol Sci. 2013 Mar;12(3):546-58
pubmed: 23258594
J Biomed Mater Res A. 2016 Sep;104(9):2334-44
pubmed: 27144507
J Biol Chem. 2014 Feb 7;289(6):3625-38
pubmed: 24347166
Exp Eye Res. 2019 Feb;179:188-192
pubmed: 30445046
Molecules. 2018 Nov 17;23(11):
pubmed: 30453653
Cornea. 2014 Jun;33(6):614-20
pubmed: 24727633
Ocul Immunol Inflamm. 2021 Feb 22;:1-11
pubmed: 33616466